IndustryCompany release

Vivos Therapeutics regains Nasdaq equity compliance as Q3 revenue rises 24% sequentially

🇺🇸 Vivos Therapeutics, Inc. (VVOS) · Tue 17 Nov 2026

The sleep apnea device company reports $6.4m quarterly revenue and a narrower operating loss, but ended September with just $0.2m in cash.

Vivos Therapeutics, a US company offering sleep apnea devices and services, reported results for the quarter ended 30 September 2026. Revenue was $6.4 million, up 24% on the previous quarter. The operating loss was $3.9 million, 18% narrower, following cost cuts.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Vivos Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Vivos Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →